Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9473387 | 0.83 | L3MBTL1 (0.51) | ALDH1A1SIGMAR1CCR5HRH3KMT2A | |
| SCHEMBL12625982 | 0.83 | ALDH1A1 (0.59) | ALDH1A1TACR1HRH3KMT2AMEN1 | |
| SCHEMBL758418 | 0.82 | HRH3 (0.50) | SIGMAR1HRH3 | |
| SCHEMBL29088788 | 0.82 | HRH3 (0.50) | KDM4EALDH1A1SIGMAR1CCR5TACR1 | |
| SCHEMBL7218152 | 0.82 | ALDH1A1 (0.63) | KDM4EALDH1A1SIGMAR1CCR5HRH3 | |
| SCHEMBL8108397 | 0.82 | ALDH1A1 (0.61) | KDM4EALDH1A1HRH3KMT2AMEN1 | |
| SCHEMBL4591888 | 0.82 | ALDH1A1 (0.59) | KDM4EALDH1A1CCR5HRH3MAPT | |
| SCHEMBL2794745 | 0.82 | TACR1 (0.55) | KDM4EALDH1A1SIGMAR1TACR1HRH3 | |
| SCHEMBL4703106 | 0.82 | ALDH1A1 (0.61) | KDM4EALDH1A1HRH3KMT2AMEN1 | |
| SCHEMBL4031743 | 0.82 | SMN1; SMN2 (0.67) | KDM4EALDH1A1SIGMAR1HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102558031-A | Synthetic method of N-p-chlorobenzyl-4-piperidone | XUZHOU COLLEGE IND TECHNOLOGY | 2012-07-11 | — | — | CN | claimed |
| EP-1856098-B1 | PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1856098-B1 | PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1856097-B1 | PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| CN-102558031-A | Synthetic method of N-p-chlorobenzyl-4-piperidone | XUZHOU COLLEGE IND TECHNOLOGY | 2012-07-11 | — | — | CN | disclosed |
| CN-102558031-A | Synthetic method of N-p-chlorobenzyl-4-piperidone | XUZHOU COLLEGE IND TECHNOLOGY | 2012-07-11 | — | — | CN | disclosed |
| CN-102558031-A | Synthetic method of N-p-chlorobenzyl-4-piperidone | XUZHOU COLLEGE IND TECHNOLOGY | 2012-07-11 | — | — | CN | disclosed |
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7868005-B2 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868005-B2 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-20020147231-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020143004-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002074056-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2001-11-29 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-4289781-A | Anti-psychotic phthalimidine derivatives | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1981-09-15 | — | — | US | disclosed |
| EP-0026749-A1 | Phthalimidine derivatives and pharmaceutical compositions containing them | Astra Läkemedel Aktiebolag (SE) | 1981-04-08 | — | — | EP | disclosed |
| US-3993470-A | ISONIPECOTIC ACID DERIVATIVES, HERBICIDES | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147231-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | KDM4E 1978/4885ALDH1A1 424/4885SIGMAR1 594/4885 |
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | CXCR3, CFTR, CXCR1 | KDM4E 3404/4885ALDH1A1 919/4885SIGMAR1 527/4885 |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | KDM4E 2701/4885ALDH1A1 291/4885SIGMAR1 631/4885 |
| US-20020143004-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | KDM4E 1899/4885ALDH1A1 328/4885SIGMAR1 545/4885 |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | KDM4E 1899/4885ALDH1A1 328/4885SIGMAR1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.